South Africa Tests First New TB Vaccine in 100 Years

For the first time in more than 100 years, the world might finally have a new weapon against tuberculosis, and South Africa is leading the charge to make it available.

The M27 vaccine has successfully completed early safety trials and is now being tested in phase three clinical trials across South Africa, Kenya, Zambia, Malawi, and Indonesia. If approved by South Africa's health authority, it would mark a historic breakthrough in fighting a disease that remains one of the world's deadliest infections.

What makes this vaccine particularly exciting is who it protects. Unlike the century-old BCG vaccine given to infants, M27 targets adolescents and adults who currently have no vaccine protection against TB. "A vaccine that prevents TB disease in adolescents and adults will be a game changer for TB control and elimination both globally and here in South Africa," said Foster Mohale, spokesperson for South Africa's Department of Health.

The country isn't waiting around to see if the trials succeed. Government officials are already preparing for the vaccine's possible registration and rollout as part of their goal to eliminate TB as a public health threat by 2030. This proactive approach means communities could access the vaccine quickly after approval, with no bureaucratic delays.

Global health partners are equally optimistic. The Gates Medical Research Institute and the Bill & Melinda Gates Foundation have secured an agreement with the Serum Institute of India to produce and supply vaccine doses worldwide if trials prove successful.

The Ripple Effect

This partnership creates exciting opportunities beyond disease prevention. The agreement opens doors for pharmaceutical collaborations in South Africa and Indonesia, potentially strengthening local vaccine manufacturing capacity. That means more than just health benefits. It could create jobs, build scientific expertise, and boost economic growth in countries that have long relied on imported medicines.

For South Africa, where TB rates remain stubbornly high, locally produced vaccines would make treatment more accessible and affordable for communities that need it most.

If everything goes according to plan, millions of people who currently live with the daily risk of TB infection could soon have real protection for the first time in their lives.